Your selection

Innovation / 06.06.2025
Eckert & Ziegler: Illuccix® PSMA-PET Imaging Agent Receives Approval in Germany

Eckert & Ziegler (ISIN DE0005659700, SDAX) congratulates Telix Pharmaceuticals Limited (Telix) on the approval of its prostate cancer PET imaging agent, Illuccix® (kit for the preparation of gallium-68 gozetotide injection) in Germany, where Eckert & Ziegler Radiopharma GmbH is the official distributor.

With Illuccix®, Eckert & Ziegler will now significantly extend its portfolio in nuclear medicine with a widely clinically validated PSMA tracer, which perfectly complements its proprietary 68Ge/68Ga Radionuclide Generator, GalliaPharm®. GalliaPharm® is widely used as a high-quality GMP grade generator for Gallium-68 in Germany and globally, supporting the production of radiopharmaceuticals for positron emission tomography (PET) imaging, particularly in oncology.

"Our collaboration with Telix on Illuccix® leverages our established distribution network and market expertise to ensure broad access to this important PSMA-PET imaging agent in Germany. This partnership reinforces our commitment to delivering advanced diagnostic solutions for prostate cancer care", commented Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE.

Raphaël Ortiz, Chief Executive Officer, Telix International added: “We are pleased that Illuccix®, which has played a key role in the advancement of PSMA-PET imaging internationally, has been approved in Germany. We are looking forward to working with Eckert & Ziegler to make our gallium-based PSMA-PET imaging agent accessible here.”

About Eckert & Ziegler
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
 

Source: Press Release Eckert & Ziegler
Eckert & Ziegler: Illuccix® PSMA-PET Imaging Agent Receives Approval in Germany

Overview News

News Buch Berlin

Berlin honors outstanding deep-tech companies—including MyoPax

This year, for the first time, a Deep Tech Award was presented in the Bio & Health Tech category. The winner is MyoPax, a spin-off of the Max Delbrück Center and Charité.

more ...

Eckert & Ziegler Receives “Best Managed Companies Award” Once Again

Eckert & Ziegler SE (ISIN DE0005659700) has won the “Best Managed Companies Award” for the third time in a row. With this honor, Deloitte Private, UBS, Frankfurter Allgemeine Zeitung, and the Federati...

more ...

Eckert & Ziegler with a Successful Start to the Year. 2026 Forecast Confirmed.

Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased its sales in the first quarter of 2026 by 7% to €72.9 million compared with the same period last year.

more ...

Events Buch Berlin

28.05.2026, 18:00
Claire-Waldoff-Abend mit Sigrid Grajek

Eine musikalische Biografie "Ich will aber gerade vom Leben singen..."

more ...

28.05.2026, 19:00
Lesung mit Sky du Mont: "Der nächste Fehler kommt bestimmt"

Der Schauspieler und Bestseller-Autor präsentiert sein neues Buch

more ...

30.05.2026, 11:30
Tag der offenen Tür im Speicher, Stadtgut Hobrechtsfelde

Zum "Tag der brandenburgischen Baukultur" präsentiert sich der Speicher als Ort des Wandels

more ...

This website is supported by: